Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

Bibliographic Details
Main Authors:	Enrico Ammirati, Cristina Cavalotti, Angela Milazzo, Patrizia Pedrotti, Francesco Soriano, Jan W. Schroeder, Nuccia Morici, Cristina Giannattasio, Maria Frigerio, Marco Metra, Paolo G. Camici, Fabrizio Oliva
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	International Journal of Cardiology: Heart & Vasculature
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352906721000622

Similar Items

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
by: Shai Efrati, et al.
Published: (2021-08-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
by: Polack, Fernando P, et al.
Published: (2021)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
by: Claudius Speer, et al.
Published: (2021-08-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
by: Marcello Salvaggio, et al.
Published: (2021-09-01)

Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans
by: Casas, J.P, et al.
Published: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
by: B Roca, et al.
Published: (2021-01-01)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)

Effectiveness of BNT162B2 Vaccine against Critical Covid-19 in Adolescents
by: Bhumbra, S.S, et al.
Published: (2022)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
by: Emanuel Zitt, et al.
Published: (2021-06-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
by: Timothy A. Bates, et al.
Published: (2021-08-01)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
by: Salvatore Zaffina, et al.
Published: (2021-06-01)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-08-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
by: Yusuke Okada, et al.
Published: (2021-09-01)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
by: Madison Ballman, BA, et al.
Published: (2021-10-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
by: Luca Coppeta, et al.
Published: (2021-08-01)

Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
by: Ilir Alimehmeti
Published: (2021-01-01)

Deep Vein Thrombosis and Pulmonary Thrombosis After BNT162b2 mRNA SARS-CoV2 Vaccination
by: Iwashima, S., et al.
Published: (2022)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
by: Jose L Casado, et al.
Published: (2021-01-01)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
by: Gili Regev-Yochay, et al.
Published: (2021-08-01)

Bibliometric Analysis of Pfizer-BioNTech (BNT162B2): A COVID-19 Vaccine
by: Waseem Hassan, et al.
Published: (2021-09-01)

Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
by: David San Segundo, et al.
Published: (2021-07-01)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
by: Jean-Louis Bayart, et al.
Published: (2021-06-01)

Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
by: Karolina Polewska, et al.
Published: (2021-07-01)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
by: Jia Ming Low, et al.
Published: (2021-08-01)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
by: Bei Wang, et al.
Published: (2021-10-01)

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
by: Brent Appelman, et al.
Published: (2021-10-01)

BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers
by: Federico Pratesi, et al.
Published: (2021-06-01)

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
by: Federico Gobbi, et al.
Published: (2021-03-01)

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
by: Raul Pellini, et al.
Published: (2021-06-01)